{"id":"bta798","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BTA798 works by binding to the SARS-CoV-2 main protease, which is essential for the virus's replication. This binding prevents the protease from processing viral proteins, ultimately inhibiting the virus's ability to replicate. As a result, BTA798 has antiviral effects against SARS-CoV-2.","oneSentence":"BTA798 is a small molecule inhibitor of the SARS-CoV-2 main protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:06:03.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT02877264","phase":"PHASE1","title":"A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Aviragen Therapeutics","startDate":"2016-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT02367313","phase":"PHASE2","title":"A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection","status":"COMPLETED","sponsor":"Biota Pharmaceuticals, Inc.","startDate":"2015-02","conditions":"Asthma","enrollment":455},{"nctId":"NCT01175226","phase":"PHASE2","title":"A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection","status":"COMPLETED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2010-08","conditions":"Rhinovirus","enrollment":300},{"nctId":"NCT02204501","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2014-05","conditions":"Drug-Drug Interaction Healthy Volunteers","enrollment":24},{"nctId":"NCT03024177","phase":"PHASE2","title":"A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection","status":"WITHDRAWN","sponsor":"Vaxart","startDate":"","conditions":"Rhinovirus, Upper Respiratory Tract Infection","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BTA798","genericName":"BTA798","companyName":"Biota Scientific Management Pty Ltd","companyId":"biota-scientific-management-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTA798 is a small molecule inhibitor of the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}